AbbVie 2014 Annual Report Download - page 164

13NOV201221352027
Nonqualified Deferred Compensation
................................................................................................................................................................................................................................................................................................................................................................................................
The following table summarizes Ms. Schumacher’s and Mr. Chase’s non-qualified deferred compensation under
the AbbVie Deferred Compensation Plan. No additional contributions have been made to their accounts under the plan
since such time as Ms. Schumacher and Mr. Chase, respectively, became officers and ceased to be eligible to contribute
to the plan. None of the other NEOs has any non-qualified deferred compensation under the plan.
L. Schumacher Deferred Compensation Plan(1)(2) $0 $0 $27,927 $0 $383,610
W. Chase Deferred Compensation Plan(1)(2) 0 0 4,386 0 71,181
(1) Ms. Schumacher’s and Mr. Chase’s contributions to the Deferred Compensation Plan ceased in 2002 and 2007,
respectively.
(2) The plan permits participants to defer up to 75% of their base salary and up to 100% of their annual cash
incentives and credits a participant’s account with an amount equal to the employer matching contributions that
otherwise would have been made for the participant under AbbVie’s tax-qualified defined contribution plan.
Participants may direct the investment of their deferral accounts into one or more of several funds chosen by the
administrator, and the deferral account is credited with investment returns based on the performance of the fund(s)
selected. During 2014, the weighted average rate of return credited to the accounts was 7.8% for Ms. Schumacher
and 6.6% for Mr. Chase.
The plan provides for cash distributions in either a lump sum or installments after separation from service and
permits in-service withdrawals in accordance with specific procedures. Participants make distribution elections each
year that apply to the deferrals to be made in the following calendar year, in accordance with the requirements of
Internal Revenue Code Section 409A. Participants may request withdrawals due to financial hardship; if a hardship
withdrawal is approved, it is limited to the amount needed to address the hardship.
(3) The amounts reported in this column are not included in the Summary Compensation Table of this proxy
statement.
(4) The amounts reported in this column have not been previously reported as compensation in AbbVie’s Summary
Compensation Tables because they relate to contributions made before the applicable individual became an NEO.
Potential Payments upon Termination or Change in Control
................................................................................................................................................................................................................................................................................................................................................................................................
Potential Payments upon Termination—Generally
AbbVie does not have employment agreements with its NEOs.
The following summarizes the payments that the NEOs would have received if their employment had terminated
on December 31, 2014. Earnings would have continued to be paid for the NEO’s Performance Incentive Plan and
Supplemental Savings Plan grantor trusts until the trust assets were fully distributed. The amount of these payments
would depend on the period over which the trust assets were distributed and the trust earnings and fees. If the trust
assets were distributed over a 10-year period and based on current earnings, the NEOs would receive the following
average annual payments over such 10-year period: Mr. Gonzalez, $721,197; Mr. Alban, $388,363; Ms. Schumacher,
$487,603; and Mr. Chase, $460,909. In addition, the following one-time deposits would have been made under the
AbbVie Supplemental Pension Plan for each of the following NEOs, respectively: Mr. Gonzalez, $2,232,027; Mr. Alban,
$1,361,973; Ms. Schumacher, $845,411; and Mr. Chase, $534,672. As of December 31, 2014, Mr. Gonzalez, Mr. Alban and
Ms. Schumacher were eligible to retire, and therefore were eligible to receive the pension benefits described above.
If the termination of employment had been due to disability, then the NEOs also would have received, in
addition to AbbVie’s standard disability benefits, a monthly long-term disability benefit in the amount of $175,000 for
44 2015 Proxy Statement
Executive Registrant Aggregate Aggregate Aggregate
contributions contributions earnings withdrawals/ balance at
in last FY in last FY in last FY distributions last FYE
Name Plan Name ($) ($) ($)(3) ($) ($)(4)
EXECUTIVE COMPENSATION